Allogene Therapeutics develops allogeneic chimeric antigen receptor T cell, or AlloCAR T, product candidates for cancer and autoimmune disease. The clinical-stage biotechnology company focuses on off-the-shelf CAR T approaches, including cemacabtagene ansegedleucel, or cema-cel, in large B-cell lymphoma and ALLO-329, a dual CD19/CD70 CAR T candidate for autoimmune diseases.
Recurring news covers clinical and regulatory updates for Allogene's studies, scientific presentations and publications, platform technologies such as Dagger®, and data related to MRD-guided treatment approaches. Company updates also include quarterly financial results, business updates, shareholder matters, and common stock financing activity tied to research, development, clinical trials, and corporate operations.
Allogene (Nasdaq: ALLO) reported Q4 and full-year 2025 results and provided program updates. Key points: $258.3 million in cash and investments as of Dec 31, 2025; cash runway extended into Q1 2028. Pivotal ALPHA3 interim futility analysis planned for April 2026; RESOLUTION data expected June 2026.
2025 net loss was $190.9 million; guidance for 2026 operating cash expense is ~$150 million and GAAP operating expenses ~$210 million.
Allogene Therapeutics (NASDAQ: ALLO) will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
According to the company, the listen-only webcast will be available on its investor website, with a replay accessible for about 30 days. Registered participants who request to speak will receive a personal PIN.
Allogene Therapeutics (Nasdaq: ALLO) will participate in two investor conferences in Q1 2026: Citi's 2026 Virtual Oncology Leadership Summit on Feb 18, 2026 at 9:15 AM PT / 12:15 PM ET and TD Cowen 46th Annual Health Care Conference on Mar 3, 2026 at 8:50 AM PT / 11:50 AM ET. Any available webcasts and replays will be posted on the company website under Investors > News and Events.
Allogene Therapeutics (Nasdaq: ALLO) positioned 2026 as a program-defining year with multiple H1 clinical readouts aimed at validating off-the-shelf AlloCAR T across oncology and autoimmune disease. Key near-term milestones include an early Q2 2026 interim futility analysis of MRD clearance from the pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation LBCL and initial proof-of-concept data for ALLO-329 (dual CD19/CD70 with Dagger®) by end of 1H 2026. The platform targets manufacturing scale of ~30,000–60,000+ doses annually and a COGS profile of <$10K–20K per dose. ALLO-316 showed a 31% confirmed ORR in high CD70 RCC patients. Cash runway is expected into 2H 2027 (excludes BD activity).
Allogene (Nasdaq: ALLO) announced a favorable arbitration ruling that reconfirms its full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the United States, all EU member states, and the United Kingdom and clears a path to obtain full global commercialization rights from Servier.
The tribunal rejected Cellectis’s claims, found milestone payments tied to the pivotal trial are due only upon FDA acceptance of a BLA, and limited license termination to the UCART19 V1 product (ALLO-501). Allogene expects a meaningful catalyst with a 1H 2026 interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation for large B-cell lymphoma (LBCL).
Allogene Therapeutics (Nasdaq: ALLO) will participate in three investor conferences in November and December 2025. Scheduled events:
- TD Cowen Immunology & Inflammation Virtual Summit — Wednesday, November 12 at 1:30 PM PT / 4:30 PM ET.
- Jefferies Global Healthcare Conference, London — Tuesday, November 18 at 2:00 AM PT / 5:00 AM ET / 10:00 AM GMT.
- Piper Sandler 37th Annual Healthcare Conference — Tuesday, December 2 at 9:00 AM PT / 12:00 PM ET.
Allogene Therapeutics (Nasdaq: ALLO) reported Q3 2025 results and provided program updates on November 6, 2025. Key financials: $277.1M in cash, cash equivalents and investments as of Sept 30, 2025, with cash runway projected into 2H 2027 and an expected 2025 cash decline of ~$150M. Q3 operating metrics: R&D $31.2M, G&A $13.7M, and net loss $41.4M ( $0.19/share). GAAP operating expenses guidance for 2025 is ~$230M including ~$45M stock-based comp.
Clinical milestones: pivotal Phase 2 ALPHA3 futility analysis (MRD conversion) on track for 1H 2026; ALLO-329 RESOLUTION PoC and biomarker update planned for 1H 2026; ALLO-316 showed durable responses in RCC and TRAVERSE completed Phase 1b enrollment.
Allogene (Nasdaq: ALLO) will present a Trial-in-Progress poster on the pivotal Phase 2 ALPHA3 study at the 2025 ASH Annual Meeting in Orlando.
ALPHA3 is a randomized, open-label trial testing cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation for patients with large B-cell lymphoma (LBCL) who remain MRD-positive after 1L chemoimmunotherapy, comparing cema-cel after standard FC lymphodepletion versus observation. A futility analysis on MRD conversion is expected in 1H 2026. Poster: Session 628, Poster II, Publication 3730; presenter John Burke, MD; display on Dec 7, 2025, 6:00–8:00 PM ET at OCCC West Halls B3-B4.
Allogene Therapeutics (Nasdaq: ALLO) will report third quarter 2025 financial results and provide a business update on November 6, 2025 after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
The listen-only webcast will be available via the company website under Investors > News and Events, and a replay will be posted for approximately 30 days. Investors who wish to ask questions must register for the conference call to receive a personal PIN to access the call.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.
The presentation is scheduled for Wednesday, September 3, at 7:30 AM PT/10:30 AM ET. Investors can access the webcast through Allogene's website, with replays available for approximately 30 days after the event.